FORTIOR (01304) announces its first three quarters results, with net profit attributable to shareholders of RMB284 million, up 69.63% year-on-year.
FORTIOR (01304) announces its results for the first three quarters of 2026. The Group recorded operating revenue of RMB842 million, up 50.88% year-on-year; net profit attributable to shareholders of the listed company of RMB284 million, up 69.63% year-on-year; and basic earnings per share of RMB2.47.
FORTIOR (01304) announces its results for the first three quarters of 2026. The Group recorded operating revenue of RMB842 million, up 50.88% year-on-year; net profit attributable to shareholders of the listed company of RMB284 million, up 69.63% year-on-year; and basic earnings per share of RMB2.47.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process
Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares
CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
Jiangsu Hengrui Pharmaceuticals (01276): Marketing authorization application for trastuzumab rezetecan for injection accepted and included in priority review process
Hua Hong Grace Semiconductor (01347): Chairman and President proposes share repurchase of the company's A-shares
CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net profit for the first three quarters was RMB60.5883 million, a year-on-year decrease of 82.34%
